A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia. Issue 10 (2nd October 2016) - Tantravahi, Srinivas K.; Szankasi, Philippe; Khorashad, Jamshid S.; Dao, Kim-Hien; Kovacsovics, Tibor; Kelley, Todd W.; Deininger, Michael W.